Cantargia Presents Clinical Data From its Ongoing CANFOUR Trial at ESMO
09 Oct, 2018, 07:46 BST
STOCKHOLM, Oct. 9, 2018 /PRNewswire/ -- Cantargia AB (publ) today announced that interim results from its clinical Phase I/II trial of lead candidate CAN04 (nidanilimab) will be presented in a poster presentation at the ESMO Congress 2018 in Munich, Germany, on October 20, 2018.
The poster presentation – with the title A first-in-class, first-in-human phase I/IIa trial of CAN04, targeting Interleukin-1 Receptor Accessory Protein (IL1RAP), in patients with solid tumors – will be given by the coordinating investigator Professor Ahmad Awada, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium. The poster is scheduled to be presented during the Poster Display session on October 20, from 12:30 to 13:30. The abstract is available on ESMO's website, www.esmo.org (see abstract 1172P).
"We are honored that CAN04 data has been selected for presentation at this prestigious conference. It shows that there is a great interest for our clinical program in the scientific community," said Göran Forsberg, CEO of Cantargia.
The primary objective of the Phase I part of CANFOUR was to assess safety and tolerability of weekly CAN04 in order to define the Maximum Tolerated Dose/Recommended Phase 2 Dose. Patients with relapsed or refractory non-small cell lung cancer (NSCLC), pancreatic ductal adenocarcinoma (PDAC), breast or colorectal cancer were included in the initial part of the trial using a 3+3 dose escalation design.
The abstract, with interim data from submission in May 2018, showed that CAN04 demonstrated a manageable safety profile up to 3 mg/kg with no dose limiting toxicity observed. The poster will include additional data as obtained until September 2018. The poster will be published in parallel with the presentation on October 20 on Cantargia's website, www.cantargia.com.
In August, Cantargia announced that 15 patients had been treated and CAN04 showed a good safety profile. A few more patients will be treated to establish maximum tolerated or recommended dose. In the Phase IIa part of the study, which is expected to start in Q4 2018, the number of clinical sites will be increased.
This constitutes information that Cantargia AB is required to publish under the EU's Market Abuse Regulation. The information was submitted for publication through the above contact person on 9 October 2018, at 8:30 a.m.
About Cantargia
Cantargia AB (publ), reg.no. 556791-6019, is a biotech company that is developing antibody-based treatments for life-threatening diseases. The original discovery by the research team behind Cantargia was the overexpression of a specific target molecule, interleukin 1 receptor accessory protein (IL1RAP) in leukemic stem cells. Subsequent research has also identified IL1RAP in many other forms of cancer. The company's main project, the CAN04 (nidanilimab) antibody targeted against IL1RAP, is being studied in the CANFOUR clinical phase I/IIa study, where the primary focus is on non-small cell lung cancer and pancreatic cancer. CAN04 (nidanilimab) has two modes of action: it blocks the function of IL1RAP and stimulates the immune system to destroy tumour cells. Cantargia's second project, currently in the research phase, is aimed at developing an IL1RAP-binding antibody that is optimised for treatment of autoimmune and inflammatory diseases.
Cantargia is listed on Nasdaq Stockholm (ticker: CANTA). More information about Cantargia is available at http://www.cantargia.com.
For further information, please contact
Göran Forsberg, CEO
Telephone: +46(0)46-275 62 60
E-mail: goran.forsberg@cantargia.com
This information was brought to you by Cision http://news.cision.com
The following files are available for download:
Related Links
SOURCE Cantargia AB